var data={"title":"Hetastarch (Hydroxyethyl starch 450/0.7; Hespan, Hextend): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hetastarch (Hydroxyethyl starch 450/0.7; Hespan, Hextend): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6312?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hetastarch-hydroxyethyl-starch-450-0-7-hespan-hextend-drug-information\" class=\"drug drug_general\">see &quot;Hetastarch (Hydroxyethyl starch 450/0.7; Hespan, Hextend): Drug information&quot;</a> and <a href=\"topic.htm?path=hetastarch-hydroxyethyl-starch-450-0-7-hespan-hextend-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hetastarch (Hydroxyethyl starch 450/0.7; Hespan, Hextend): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50370214\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Treatment-related mortality and renal replacement therapy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In critically ill adults, including patients with sepsis, use of hydroxyethyl starch (HES) products increases the risk mortality and renal replacement therapy.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Do not use HES products, including hetastarch, in critically ill adults, including patients with sepsis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179043\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Hespan;</li>\n      <li>Hextend</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179044\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Hextend</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059235\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Plasma Volume Expander</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059230\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=hetastarch-hydroxyethyl-starch-450-0-7-hespan-hextend-drug-information\" class=\"drug drug_general\">see &quot;Hetastarch (Hydroxyethyl starch 450/0.7; Hespan, Hextend): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> With severe dehydration, administer crystalloid first. Dose and rate of infusion dependent on amount of blood lost, on maintenance or restoration of hemodynamics, and on amount of hemodilution. Titrate to individual colloid needs, hemodynamics, and hydration status. Do not use in critically ill patients, those undergoing open heart surgery with cardiopulmonary bypass, or those with preexisting renal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children and Adolescents: <b>Volume expansion:</b> IV infusion:  Very limited data available: Children &ge;1 year and Adolescents: 10  mL/kg/dose; dosing based on a small randomized, double-blinded study of 38 patients (age range: 1-15.5 years) compared hetastarch (n=20) and albumin (n=18) as a postoperative volume expander in the first 24 hours after congenital heart surgery; no differences in safety compared to albumin were found at hetastarch daily doses &le;20 mL/kg/day; patients receiving doses of 20-30 mL/kg/day were noted to have an increased PT; however, there was no difference in clinical bleeding; doses &gt;30 mL/kg have not been studied (Brutacao, 1996). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Plasma volume expansion:</b> IV infusion: 500-1000 mL (up to 1500 mL/day) or 20 mL/kg/day (up to 1500 mL/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Leukapheresis</b> (Hespan&reg;): IV infusion: 250-700 mL; <b>Note:</b> Citrate anticoagulant is added before use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults: Avoid use in patients with pre-existing renal dysfunction. Use is contraindicated in renal failure with oliguria or anuria (not related to hypovolemia). Discontinue use at the first sign of renal injury.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults: No dosage adjustment provided in manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179025\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hespan: 6% (500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hextend: 6% (500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 6% (500 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179010\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059238\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: IV: Administer IV only; may be administered via infusion pump or pressure infusion; if administered by pressure infusion, air should be withdrawn or expelled from bag prior to infusion to prevent air embolus. Administration rates vary depending upon the extent of blood loss, age, and clinical condition of patient but, in general, should not exceed 1.2 <b>g</b>/kg/<b>hour</b> (20 mL/kg/<b>hour</b>) in adults. Change IV tubing or flush copiously with normal saline before administering blood through the same line. Do not administer Hextend&reg; with blood through the same administration set. Change IV tubing at least every 24 hours. Anaphylactoid reactions can occur; have epinephrine and resuscitative equipment available. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179038\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Store at 25&deg;C (77&deg;F); avoid excessive heat; do not freeze. Brief exposure up to 40&deg;C (104&deg;F) does not adversely affect the product. Avoid excessive heat. Do not use if crystalline precipitate forms or is turbid deep brown.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hespan: In leukapheresis, admixtures of 500 to 560 mL of hetastarch with citrate concentrations up to 2.5% are compatible for 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059237\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of hypovolemia (Hespan&reg; and Hextend&reg;: FDA approved in adults); adjunctive use during leukapheresis to improve granulocyte harvesting and increase the yield of granulocytes by centrifucation (Hespan&reg;: FDA approved in adults); <b>Note:</b> This is not a substitute for blood or plasma; does not have oxygen-carrying capacity. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179084\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Hespan may be confused with heparin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179081\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, cardiac failure, increased plasma volume, peripheral edema, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, headache, intracranial hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus (dose dependent; may be delayed), skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypervolemia, increased amylase (transient), metabolic acidosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Parotid gland enlargement, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, blood coagulation disorder (Factor VIII deficiency, acquired von Willebrand's like syndrome, dilutional coagulopathy), disseminated intravascular coagulopathy (rare), hemolysis (rare), hemorrhage, prolonged bleeding time, prolonged partial thromboplastin time, prolonged prothrombin time, thrombocytopenia, wound hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum bilirubin (indirect)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction, hypersensitivity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, flu-like symptoms (mild), non-cardiogenic pulmonary edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Angioedema, cough, erythema multiforme, facial edema, hypotension, laryngeal edema, periorbital edema, renal insufficiency, severe hypotension, stridor, submaxillary gland enlargement, tachypnea, urticaria, ventricular fibrillation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179030\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to hetastarch, hydroxyethyl starch (HES), or any component of the formulation; renal disease with oliguria or anuria (not related to hypovolemia); any fluid overload condition (eg, pulmonary edema, heart failure); preexisting coagulation or bleeding disorders; critically ill adults, including patients with sepsis; severe liver disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hextend: Additional contraindications: Treatment of lactic acidosis; leukapheresis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179014\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid reactions: Life-threatening anaphylactic/anaphylactoid reactions, including death, have been reported (rarely); discontinue use immediately with signs of hypersensitivity and administer appropriate therapy. Patients allergic to corn may be allergic to hetastarch.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: Not recommended for use as a cardiac bypass pump prime, while the patient is on cardiopulmonary bypass, or in the period immediately afterward. HES solutions have been associated with excess bleeding in these patients. Monitor the coagulation status in patients undergoing open heart surgery in association with cardiopulmonary bypass. Discontinue use of HES at the first sign of coagulopathy. May cause coagulation abnormalities in conjunction with a reversible, acquired von Willebrand-like syndrome and/or factor VIII deficiency when used over a period of days. Consider replacement therapy if a severe factor VIII deficiency is detected. Coagulopathies may take several days to resolve. When used to prevent cerebral vasospasm in patients with subarachnoid hemorrhage (off-label use), significant clinical bleeding, intracranial bleeding and death have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid overload: Administration may cause fluid overload; use with caution in patients at risk from overexpansion of blood volume (eg, very young, elderly patients); use is contraindicated in heart failure or any preexisting condition where volume overload is a potential concern.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic: Large volumes of hetastarch may cause a reduction in hemoglobin concentration, coagulation factors, and other plasma proteins due to hemodilution; when used for leukapheresis, frequent clinical evaluation and complete blood counts (CBC) are recommended. If leukapheresis frequency is greater than whole blood donation guidelines, consider monitoring total leukocyte and platelet counts, leukocyte differential, PT, and PTT as well. Coagulation may be impaired (eg, prolonged PT, PTT, and clotting times) and a transient prolongation of bleeding time may be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment; use is contraindicated in patients with severe hepatic impairment. Monitor liver function at baseline and periodically during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Avoid use in patients with preexisting renal impairment; monitor fluid status, urine output, and infusion rate; discontinue use at the first sign of renal injury. Larger hetastarch molecules may leak into urine in patients with glomerular damage; may elevate urine specific gravity. Use is contraindicated in renal disease with oliguria or anuria not related to hypovolemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombocytopenia: Use with caution in patients with thrombocytopenia; large volumes may interfere with platelet function and transiently prolong bleeding time. Observe for bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Critically-ill patients: <b>[US Boxed Warning]: HES solutions have been associated with mortality and renal injury requiring renal replacement therapy in critically ill patients, including patients with sepsis; avoid use in critically ill adults, including those with sepsis.</b> Use should also be avoided in patients admitted to the ICU (Brunkhorst 2008; Perel 2011; Perner 2012; Zarychanski 2009). The Society of Critical Care Medicine (SCCM) also recommends against the use of HES solutions (ie, colloids) for fluid resuscitation of severe sepsis and septic shock; crystalloids (eg, sodium chloride, Ringer's lactate) are recommended as the fluid of choice for initial resuscitation and subsequent intravascular volume replacement (Rhodes 2017). If used in patients who are not critically ill, avoid use in patients with preexisting renal impairment and discontinue use at the first sign of renal injury. Since the need for renal replacement therapy has been reported up to 90 days after HES administration, continue to monitor renal function in all patients for at least 90 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hextend: Contains calcium, lactate and potassium; use with caution in situations where electrolyte and/or acid-base disturbances may be exacerbated (renal impairment, respiratory alkalosis, metabolic alkalosis). Do not use in leukapheresis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not a substitute for red blood cells or coagulation factors.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26535447\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Hetastarch use has been associated with acute kidney injury in pediatric patients (Reinhart, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299443\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220790\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13350&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Arbekacin: Hetastarch may enhance the nephrotoxic effect of Arbekacin. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179020\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13888219\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059234\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Volume expansion: Blood pressure, capillary refill time, CVP, RAP, MAP, urine output, heart rate, if pulmonary artery catheter in place, monitor cardiac index, PWCP, SVR, and PVR; hemoglobin, hematocrit, serum electrolytes, renal function (continue to monitor for at least 90 days after administration), acid-base balance, coagulation parameters, platelets </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leukapheresis, CBC, total leukocyte and platelet counts, leukocyte differential count, hemoglobin, hematocrit, prothrombin time, and partial thromboplastin time </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179013\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Produces plasma volume expansion by virtue of its highly colloidal starch structure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179029\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: 3 to 36 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~33% within 24 hours); smaller molecular weight molecules (&lt;50,000 daltons) rapidly excreted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059243\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Hetastarch is a synthetic polymer derived from a waxy starch composed of amylopectin, average molecular weight of Hespan&reg; is 600,000 kDa (range: 450,000-800,000 kDa), average molecular weight of Hextend&reg; is 670,000 kDa (range: 450,000-800,000 kDa); each liter of Hespan&reg; provides 154 mEq sodium chloride; each liter of Hextend&reg; contains the following electrolytes: Sodium 143 mEq, chloride 124 mEq, lactate 28 mEq, calcium 5 mEq, magnesium 0.9 mEq, potassium 3 mEq, and dextrose 0.99 g</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323182\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Hespan Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6-0.9% (500 mL): $15.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Hetastarch-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6-0.9% (500 mL): $15.05</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Hextend Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6% (500 mL): $78.18</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038650\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Elohaes (HR, NL);</li>\n      <li>Elohaest (AT);</li>\n      <li>Farhes (ID);</li>\n      <li>Haes Steril (AE, EG, LB);</li>\n      <li>HAES-steril (BE, HR, LU, NL, PL);</li>\n      <li>Haes-Steril (BG, BH, CH, CN, CZ, DE, ES, GB, GR, HN, ID, IL, IN, PH, RU, SA, SG, TH);</li>\n      <li>Hemohes (AR, CL, LU, NL);</li>\n      <li>Hespander (JP);</li>\n      <li>Hestar-200 (CO, ID);</li>\n      <li>Hydroksyetyloskrobia (PL);</li>\n      <li>Hyper HAES (DK, EE, FI, SE);</li>\n      <li>HyperHAES (PL);</li>\n      <li>Hyperhes (AT, FR);</li>\n      <li>Infukoll HES (PL);</li>\n      <li>Plasmasteril (BE, PL, TR);</li>\n      <li>StarQuin (NZ);</li>\n      <li>Temo (TW);</li>\n      <li>Widahes (ID);</li>\n      <li>Widahes-130 (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Brutocao D, Bratton SL, Thomas JR, et al, &ldquo;Comparison of Hetastarch With Albumin for Postoperative Volume Expansion in Children After Cardiopulmonary Bypass,&rdquo; <i>J Cardiothoracic Vasc Anesth</i>, 1996, 10(3):348-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-450-0-7-hespan-hextend-pediatric-drug-information/abstract-text/8725415/pubmed\" target=\"_blank\" id=\"8725415\">8725415</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brunkhorst FM, Engel C, Bloos F, et al, &ldquo;Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis,&rdquo; <i>N Engl J Med</i>,  2008, 358(2):125-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-450-0-7-hespan-hextend-pediatric-drug-information/abstract-text/18184958/pubmed\" target=\"_blank\" id=\"18184958\">18184958</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dellinger RP, Levy MM, Rhodes A, et al, &quot;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012,&quot; <i>Crit Care Med</i>, 2013, 41(2):580-637.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-450-0-7-hespan-hextend-pediatric-drug-information/abstract-text/23353941/pubmed\" target=\"_blank\" id=\"23353941\">23353941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perel P and Roberts I, &ldquo;Colloids Versus Crystalloids for Fluid Resuscitation in Critically Ill Patients,&rdquo; <i>Cochrane Database Syst Rev</i>, 2012, 6:CD000567.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-450-0-7-hespan-hextend-pediatric-drug-information/abstract-text/22696320/pubmed\" target=\"_blank\" id=\"22696320\">22696320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perner A, Haase N, Guttormsen AB, et al, &ldquo;Hydroxyethyl Starch 130/0.4 Versus Ringer's Acetate in Severe Sepsis,&rdquo; <i>N Engl J Med</i>, 2012, 367(2):124-34; published erratum appears in <i>N Engl J Med</i>, 2012, 367(5):481.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-450-0-7-hespan-hextend-pediatric-drug-information/abstract-text/22738085/pubmed\" target=\"_blank\" id=\"22738085\">22738085</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reinhart K, Perner A, Sprung CL, et al, &ldquo;Consensus Statement of the ESICM Task Force on Colloid Volume Therapy in Critically Ill Patients,&rdquo; <i>Intensive Care Med</i>, 2012, 38(3):368-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-450-0-7-hespan-hextend-pediatric-drug-information/abstract-text/22323076/pubmed\" target=\"_blank\" id=\"22323076\">22323076</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zarychanski R, Turgeon AF, Fergusson DA, et al, &ldquo;Renal Outcomes and Mortality Following Hydroxyethyl Starch Resuscitation of Critically Ill Patients: Systematic Review and Meta-Analysis of Randomized Trials&rdquo; <b>ATTENTION:</b> The analysis and conclusions of this article are being revised by the authors. This is due to the journal Anesthesia and Analgesia's retraction of a paper by Dr. Joachim Boldt, an author in seven of the studies analyzed in this review. As such, the editors of Open Medicine recommend interpreting this review with extreme caution until Zarychanski et al. publish a new analysis and interpretation in Open Medicine. For more information, see Anesthesia and Analgesia's press release. Open Med, 2009, 3(4):e196-209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-450-0-7-hespan-hextend-pediatric-drug-information/abstract-text/21688756/pubmed\" target=\"_blank\" id=\"21688756\">21688756</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13350 Version 99.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F50370214\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F179043\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F179044\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1059235\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1059230\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F179025\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F179010\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1059238\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F179038\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1059237\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F179084\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F179081\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F179030\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F179014\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26535447\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299443\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220790\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F179020\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13888219\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1059234\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F179013\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F179029\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1059243\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323182\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038650\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13350|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hetastarch-hydroxyethyl-starch-450-0-7-hespan-hextend-drug-information\" class=\"drug drug_general\">Hetastarch (Hydroxyethyl starch 450/0.7; Hespan, Hextend): Drug information</a></li><li><a href=\"topic.htm?path=hetastarch-hydroxyethyl-starch-450-0-7-hespan-hextend-patient-drug-information\" class=\"drug drug_patient\">Hetastarch (Hydroxyethyl starch 450/0.7; Hespan, Hextend): Patient drug information</a></li></ul></div></div>","javascript":null}